论文部分内容阅读
目的:回顾性分析单纯化疗、化疗+DC-CIK细胞治疗、化疗+自体造血干细胞移植治疗的3种免疫细胞治疗急性中危组白血病的疗效。方法:将2009年1月-2012年12月本院65例急性中危组白血病患者,随机分成三组,分别给予单纯化疗(21例)、化疗+DC-CIK细胞治疗(26化疗+例)、化疗+自体造血干细胞移植(18例),采用健康供着(患者的父母或子女或婴儿脐带组织)单个核细胞,制备DC-CIK细胞,每位患者输注4~6次,每次间隔30 d。治疗结束后定期复查患者三年生存率、治疗费用、MDR检测、DC-CIK注射后产生的发热、过敏等不良反应。流式细胞术检测患者外周血淋巴细胞亚群的变化。结果:DC-CIK细胞输注未见严重不良反应发生情况。与单纯化疗组相比,化疗+DC-CIK细胞治疗方法患者体内CD3+、CD4+、CD8+、CD56+淋巴细胞均高于输注治疗前水平(P<0.01),治疗组同一随访时间段CD3+、CD4+、CD8+、CD56+淋巴细胞均显著高于化疗+自体造血干细胞移植治疗(P<0.05)。结论:化疗+DC-CIK细胞治疗方法明显优于单一化疗手段及化疗+自体造血干细胞移植。能显著提高患者肿瘤杀伤性T细胞水平,有助于清除移植后微小残留病,改善患者无病生存率。
OBJECTIVE: To retrospectively analyze the curative effects of three kinds of immune cells treated with chemotherapy, chemotherapy + DC-CIK cell therapy and chemotherapy + autologous hematopoietic stem cell transplantation in the treatment of acute intermediate-stage leukemia. Methods: From January 2009 to December 2012, 65 acute leukemia patients in our hospital were randomly divided into three groups: chemotherapy alone (21 cases), chemotherapy + DC-CIK cell therapy (+ 26 cases) , Chemotherapy + autologous hematopoietic stem cell transplantation (n = 18), DC-CIK cells were prepared using healthy mononuclear cells (patient’s parents or children or infant umbilical cord tissue), and each patient was infused 4 to 6 times per interval 30 d. After treatment, patients were regularly reviewed three-year survival rate, treatment costs, MDR test, DC-CIK injection fever, allergies and other adverse reactions. Flow Cytometry Detection of Peripheral Blood Lymphocyte Subsets in Patients. Results: There was no serious adverse reaction in DC-CIK cells. The levels of CD3 +, CD4 +, CD8 + and CD56 + lymphocytes in patients with chemotherapy + DC-CIK cell therapy were significantly higher than those before chemotherapy alone (P <0.01). The CD3 +, CD4 + CD8 +, CD56 + lymphocytes were significantly higher than chemotherapy + autologous stem cell transplantation (P <0.05). Conclusion: Chemotherapy + DC-CIK cell therapy is superior to single chemotherapy and chemotherapy + autologous stem cell transplantation. Can significantly improve the level of tumor killer T cells in patients, help to clear the minimal residual disease after transplantation and improve the disease-free survival rate of patients.